Table 1.

Regional target product profiles

Target profile	South Asia	Africa
Risk:Benefit	Must be very high Parasitological cure must be achieved	No direct associated mortality with symptomatic treatment
Ease of use		Feasible to use at the level of a health clinic
Course of treatment	Very short course of treatment to facilitate compliance	Minimum acceptable treatment for children: one week (similar to antibiotics)
Cold chain requirements	Ideally not cold chain dependent
Cost factors	Cost is less important than commitment to treatment
Concomitant infections		With HIV co-infection, no antimonials or monotherapies